This agreement defines an exclusive option to
obtain licences for joint programs including Otoferlin & Usher
Type 1 and preference rights on the research pipeline in the field
of genetic disorders of the inner ear in order to set up future
collaborations
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a
pioneering clinical-stage biopharmaceutical company which
specialises in the development of novel therapies to restore, treat
and prevent inner ear diseases such as hearing loss, tinnitus and
vertigo, today announces the signature of a research partnership
framework agreement with Institut Pasteur (Paris) granting to
Sensorion an option to obtain exclusive licenses to develop and
market drug candidates in gene therapy coming from collaborative
projects, for the restoration, treatment and prevention of hearing
disorders.
In accordance with the letter of intent announced the 23rd of
November 2018, Sensorion and Institut Pasteur have leveraged the
last six months to reach a partnership framework agreement. This
agreement provides for, after completion of a research program, an
exclusive option to obtain licences. The terms of the licences are
predefined for two specific programs aiming at correcting
hereditary monogenic forms of deafness including Usher Type 1 and
deafness caused by a mutation of the gene encoding Otoferlin. As
for the other projects in the field of hereditary monogenic forms
of deafness, the terms of the licences will be negotiated in light
of the results of the research programs. Lastly, Sensorion has
preference rights on Institut Pasteur’s research programs in the
field of genetic inner ear diseases in order to set up
collaborations.
In the event of a change of control of Sensorion that has not
been approved by the Sensorion Board of Directors, Institut Pasteur
has the right to terminate the partnership framework agreement.
The Genetics and Physiology of the Hearing Unit of Institut
Pasteur, led by Professor Christine Petit, has developed
world-class expertise over the last 25 years in the molecular
physiology and physiopathology of the hearing system. Recent
advances have led to the development of gene therapy programs to
treat monogenic form of inner ear diseases. Researchers, including
the Institut Pasteur team, have managed to restore hearing in a
mouse model of DFNB9 (Otoferlin) deafness, a hearing disorder that
is one of the most common cases of congenital genetic deafness.
This work was published in a prestigious scientific journal1.
“I am particularly pleased by this agreement signed between
Institut Pasteur and Sensorion. It will allow us to transform our
scientific progress into innovations for the benefit of patients,
whether it is by contributing to create new diagnostic tools,
improving patients’ healthcare pathway or developing curative
treatments for hearing disorders,” says Professor Christine
Petit. Professor Christine Petit, MD, PhD, who chairs
Sensorion’s Scientific Advisory Board, is an internationally
renowned geneticist and neurobiologist in the field of hearing.
“We believe that the scientific work undertaken by Christine
Petit’s teams is of great interest for public health and for the
foundations of a field that is unfortunately of increasing concern.
We are delighted to work with Sensorion, a dynamic French company
with the strengths to allow Institut Pasteur to fulfil one of its
missions, i.e. to transform its first-class academic research into
products aiding patients alongside socio-economic partners,” states
Dr Isabelle Buckle, Head of Research Applications and
Industrial Relations at Institut Pasteur.
“This agreement confirms Sensorion’s strategic relationship with
the internationally renowned scientists from Institut Pasteur and I
am very pleased about this. This is a great milestone for
Sensorion, that enables us to develop the broadest pipeline with
therapeutic solutions to Prevent, Treat and Restore inner ear
diseases. In addition to the two drug candidates in development,
SENS-111 and SENS-401, we are now adding innovative drug candidates
in gene therapy allowing us to offer relevant medical solutions to
treat disabling inner ear diseases,” comments Nawal Ouzren,
Sensorion CEO.
About SensorionSensorion is a pioneering clinical-stage
biopharmaceutical company, which specializes in the development of
novel therapies to restore, treat and prevent inner ear diseases
such as hearing loss, vertigo and tinnitus. Our clinical-stage
portfolio includes two phase 2 products: Seliforant (SENS-111)
under investigation for acute unilateral vestibulopathy and
Arazasetron (SENS-401) for sudden sensorineural hearing loss
(SSNHL). We have built a unique R&D technology platform to
expand our understanding of the physiopathology and etiology of
inner ear related diseases enabling us to select the best targets
and modalities for drug candidates. We also identify biomarkers to
improve diagnosis and treatment of these underserved illnesses.
We are uniquely placed through our platforms and pipeline of
potential therapeutics to make a lasting positive impact on
hundreds of thousands of people with inner ear related disorders; a
significant global unmet need in medicine today.
www.sensorion-pharma.com
About the Institut PasteurThe Institut Pasteur, a
non-profit foundation with recognized charitable status set up by
Louis Pasteur in 1887, is today an internationally renowned center
for biomedical research with a network of 32 institutes worldwide.
In the pursuit of its mission to prevent and control diseases in
France and throughout the world, the Institut Pasteur operates in
four main areas: research, public health, education and training,
and development of research applications. More than 2,500 people
work on its Paris campus. The Institut Pasteur is a globally
recognized leader in infectious diseases, microbiology, and
immunology. Other avenues of investigation include cancer, genetic
and neurodegenerative diseases, genomics and developmental biology.
This research aims to expand our knowledge of the living world in a
bid to lay the foundations for new prevention strategies and novel
therapeutics. Since its inception, 10 Institut Pasteur scientists
have been awarded the Nobel Prize for Medicine, including two in
2008 for the 1983 discovery of the human immunodeficiency virus
(HIV) that causes AIDS.
www.pasteur.fr/en
Label: SENSORIONISIN: FR0012596468Mnemonic:
ALSEN
DisclaimerThis press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward-looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the Document de référence registration document filed
with the Autorité des marchés financiers (AMF- French Financial
Market Authority) on September 6, 2017 under n°R.17-062 and to the
development of economic conditions, financial markets and the
markets in which Sensorion operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Sensorion or not currently considered material by
Sensorion. The occurrence of all or part of such risks could cause
actual results, financial conditions, performance or achievements
of Sensorion to be materially different from such forward-looking
statements.
This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
1 Dual AAV-mediated gene therapy restores hearing in a DFNB9
mouse model. PNAS 2019 116 (10): 4496-450 Akil
O., Dyka, Calvet C., Emptoz A., Lahlou G,
Nouaille S, Boutet de Monvel J., Hardelin JP.,
Hauswirth W., Avan P., Petit C, Safieddine S., and Lustig L. Press
release
https://www.pasteur.fr/en/press-area/press-documents/gene-therapy-durably-reverses-congenital-deafness-mice
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190526005033/en/
SensorionNawal OuzrenCEOcontact@sensorion-pharma.comTel:
+33 467 207 730
Catherine LeveauFinancial
communicationcatherine.leveau@sensorion-pharma.comTel:
+33 467 207 730
Sensorion (EU:ALSEN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sensorion (EU:ALSEN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024